Viral chemokine-antigen fusion proteins
AssigneesServices, The United States of America, as represented by the Secretary, Department of Health and Human
InventorsLarry W. Kwak, Bira Arya
Life of this patent
Estimating the term…
Abstract
The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a viral chemokine fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.
Claims15
A fusion polypeptide comprising a viral chemokine and a human tumor antigen, wherein the viral chemokine comprises viral macrophage inflammatory protein III (vMIPIII).
Dependencies are inferred from the claim text.